Patent ID: 11859257
Assignee: GEN-PROBE INCORPORATED
Field: Biotechnology (Chemistry)
Classification: CPC C | IPC C

Claim 0:
1. A composition comprising:
at least one orfX amplification oligomer, at least a first SCCmec right extremity junction (MREJ) amplification oligomer and a second MREJ amplification oligomer, at least one detection oligomer comprising a non-nucleotide detectable label, a plurality of mec amplification oligomers, and at least first and second GAPDH amplification oligomers, wherein:
the orfX amplification oligomer comprises the sequence of SEQ ID NO: 59 or 60;
the first MREJ amplification oligomer comprises the sequence of SEQ ID NO: 83 including cytosine methylation or the sequence of SEQ ID NO: 84;
the orfX amplification oligomer and the first MREJ amplification oligomer are configured to produce a first orfX/SCCmec junction amplicon of a length ranging from about 200 nucleotides to about 2000 nucleotides from a MRSA of MREJ type xv;
the orfX amplification oligomer and the second MREJ amplification oligomer are configured to produce a second orfX/SCCmec junction amplicon of a length ranging from about 200 nucleotides to about 2000 nucleotides from a MRSA of one or more MREJ types different from MREJ type xv;
wherein the at least one detection oligomer comprises an orfX/SCCmec junction primary detection oligomer configured to hybridize specifically to one or more orf/SCCmec junction amplicons, including the first orfX/SCCmec junction amplicon;
the plurality of mec amplification oligomers comprises first and second mecA/mecC amplification oligomers;
the first mecA/mecC amplification oligomer is configured to specifically hybridize to a site in SEQ ID NO: 13 comprising position 1394 of SEQ ID NO: 13 and a site in SEQ ID NO: 14 comprising position 1285 of SEQ ID NO: 14, or to a site in SEQ ID NO: 13 comprising position 1484 of SEQ ID NO: 13 and a site in SEQ ID NO: 14 comprising position 1376 of SEQ ID NO: 14;
the second mecA/mecC amplification oligomer is configured to specifically hybridize to a site in SEQ ID NO: 13 comprising position 1312 of SEQ ID NO: 13 and a site in SEQ ID NO: 14 comprising position 1203 of SEQ ID NO: 14;
the first and second mecA/mecC amplification oligomers are configured to produce a mec amplicon;
the first GAPDH amplification oligomer is configured to specifically hybridize to a site in SEQ ID NO: 15 comprising position 169 or 212 of SEQ ID NO: 15;
the second GAPDH amplification oligomer is configured to specifically hybridize to a site in SEQ ID NO: 15 comprising position 279, 312, or 421 of SEQ ID NO: 15; and
the first and second GAPDH amplification oligomers are configured to produce a GAPDH amplicon.